A 2-week,polysomnographic, safety study of sodium oxybate in obstructive sleep apnea syndrome |
| |
| Authors: | Charles F P George Neil Feldman Yanping Zheng Teresa L Steininger Susanna M Grzeschik Chinglin Lai Neil Inhaber |
| |
| Institution: | (1) University of Western Ontario, London Health Sciences Centre, 375 South Street, London, ON, N6A 4G5, Canada;(2) Clinical Research Group of St. Petersburg, 2525 Pasadena Avenue South, St. Petersburg, FL 33707, USA;(3) Jazz Pharmaceuticals, Inc, 3180 Porter Drive, Palo Alto, CA 94304, USA;(4) Present address: Otsuka Pharmaceuticals, 100 Overlook Center, 1st Fl, Princeton, NJ 08540, USA;(5) Present address: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990, USA;(6) Present address: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA |
| |
| Abstract: | Purpose Sodium oxybate (SXB) is approved for cataplexy and excessive daytime sleepiness in narcolepsy. Obstructive sleep apnea syndrome
(OSAS) affects ∼9–50% of narcoleptics. Effects of 2-week SXB administration on apnea–hypopnea index (AHI), oxygen saturation
(SaO2), and sleep architecture were investigated in OSAS patients. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
